Unigene Laboratories, Inc. (OTC BB: UGNE), a biopharmaceutical company, engages in the research, production and delivery of small proteins that have shown or may potentially demonstrate medical benefits. In addition to the company’s patented manufacturing technology designed to produce many peptides cost-effectively, Unigene has patented oral and nasal delivery technologies that have demonstrated the ability to deliver medically useful amounts of various peptides into the bloodstream. For further information, visit the Company’s web site at www.unigene.com.
- 17 years ago
QualityStocks
Unigene Laboratories, Inc. (OTC BB: UGNE)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – VolitionRx (NYSE American: VNRX) Prepares Reimbursement Submission for Nu.Q Cancer Assays in France
VolitionRx Ltd. (NYSE American: VNRX) (“Volition”), a multi-national epigenetics company, announced that it is preparing a reimbursement submission for its Nu.Q®…
-
QualityStocksNewsBreaks – Brand Engagement Network Inc. (NASDAQ: BNAI) Reports Warrant Exercises, Debt Conversion, and Public Warrants Update
Brand Engagement Network Inc. (NASDAQ: BNAI) announced on Wednesday that it generated approximately $1.46 million…
-
Soligenix (NASDAQ: SNGX) Positioning for Impact in Growing Rare-Disease Landscape
The World Health Organization’s recent recognition of rare diseases as a global health priority underscores…